메뉴 건너뛰기
The Lancet Oncology
Volumn 15, Issue 6, 2014, Pages 549-550
Exploring better strategies for EGFR antibodies in colon cancer
Author keywords

[No Author keywords available]
Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PANITUMUMAB;
EID: 84899945861     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70137-8     Document Type: Note
Times cited : (6)
References (11)
  • 1
    • 84867122727 scopus 로고    scopus 로고
    • ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
    • Schmoll HJ, van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012, 23:2479-2515.
    • (2012) Ann Oncol , vol.23 , pp. 2479-2515
    • Schmoll, H.J.1    van Cutsem, E.2    Stein, A.3
  • 2
    • 84868104706 scopus 로고    scopus 로고
    • The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus
    • Adam R, De Gramont A, Figueras J, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012, 17:1225-1239.
    • (2012) Oncologist , vol.17 , pp. 1225-1239
    • Adam, R.1    De Gramont, A.2    Figueras, J.3
  • 3
    • 84883680951 scopus 로고    scopus 로고
    • Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
    • Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Eng J Med 2013, 369:1023-1034.
    • (2013) N Eng J Med , vol.369 , pp. 1023-1034
    • Douillard, J.Y.1    Oliner, K.S.2    Siena, S.3
  • 4
    • 84899969656 scopus 로고    scopus 로고
    • Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. European Cancer Congress 2013; Amsterdam, Netherlands; Sept 27-Oct 1
    • Stintzing S, Jung A, Rossius L, et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. European Cancer Congress 2013; Amsterdam, Netherlands; Sept 27-Oct 1, 2013.
    • (2013)
    • Stintzing, S.1    Jung, A.2    Rossius, L.3
  • 5
    • 84899906712 scopus 로고    scopus 로고
    • Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial
    • published online April 3.
    • Wasan H, Meade A, Adams R, et al. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncol 2014, published online April 3. http://dx.doi.org/10.1016/S1470-2045(14)70106-8.
    • (2014) Lancet Oncol
    • Wasan, H.1    Meade, A.2    Adams, R.3
  • 6
    • 79959571031 scopus 로고    scopus 로고
    • Intermittent versus continuous and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
    • Adams RA, Meade AM, Seymour MT, et al. Intermittent versus continuous and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011, 12:642-653.
    • (2011) Lancet Oncol , vol.12 , pp. 642-653
    • Adams, R.A.1    Meade, A.M.2    Seymour, M.T.3
  • 7
    • 84874645608 scopus 로고    scopus 로고
    • A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction
    • Tian S, Simon I, Moreno V, et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut 2013, 62:540-549.
    • (2013) Gut , vol.62 , pp. 540-549
    • Tian, S.1    Simon, I.2    Moreno, V.3
  • 8
    • 84887989710 scopus 로고    scopus 로고
    • Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition
    • Roepman P, Schlicker A, Tabernero J, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer 2014, 134:552-562.
    • (2014) Int J Cancer , vol.134 , pp. 552-562
    • Roepman, P.1    Schlicker, A.2    Tabernero, J.3
  • 9
    • 84877619075 scopus 로고    scopus 로고
    • A colorectal cancer classification system that associates cellular phenotype and responses to therapy
    • Sadanandam A, Lyssiotis CA, Homicsko K, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013, 19:519-525.
    • (2013) Nat Med , vol.19 , pp. 519-525
    • Sadanandam, A.1    Lyssiotis, C.A.2    Homicsko, K.3
  • 10
    • 84863000299 scopus 로고    scopus 로고
    • The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancer
    • Diaz LA, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancer. Nature 2012, 486:537-540.
    • (2012) Nature , vol.486 , pp. 537-540
    • Diaz, L.A.1    Williams, R.T.2    Wu, J.3
  • 11
    • 84898542288 scopus 로고    scopus 로고
    • Liquid biopsies: genotyping circulating tumor DNA
    • Diaz LA, Bardelli A Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014, 32:579-586.
    • (2014) J Clin Oncol , vol.32 , pp. 579-586
    • Diaz, L.A.1    Bardelli, A.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.